AT-001

DRUG4 trials

Sponsors

Alltech Life Sciences Inc., University of Kentucky, Applied Therapeutics, Inc., NYU Langone Health

Conditions

COVID-19Diabetic CardiomyopathiesOxidative Stress

Phase 1

Safety and Tolerability of Antioxidant (AT-001)for Reducing Brain Oxidative Stress

CompletedNCT01731093

Alltech Life Sciences Inc.Oxidative Stress

Start: 2012-03-31End: 2013-12-31Updated: 2014-01-23

Phase 2

Cardiovascular Effects of COVID-19

CompletedNCT04365699

NYU Langone HealthCOVID-19

Start: 2020-04-08End: 2021-01-31Updated: 2021-09-16

Phase 3

Safety and Efficacy of AT-001 in Patients With Diabetic Cardiomyopathy

Active, not recruitingNCT04083339

Applied Therapeutics, Inc.Diabetic Cardiomyopathies

Start: 2019-09-20End: 2025-12-31Target: 675Updated: 2022-12-08

Unknown Phase

AT-001 for Long-term Preservation of Brain Health in Aging

CompletedNCT03062384

University of KentuckyOxidative Stress

Start: 2016-05-31End: 2018-12-31Updated: 2019-08-20

Related Papers

Sex Differences in Diabetic Cardiomyopathy and Treatment Response to AT-001: Insights From the ARISE-HF Study.

2025-05-082 citations

Health status in stage B heart failure from diabetic cardiomyopathy baseline results from ARISE-HF.

2025-04-25

Impaired Exercise Capacity in High-Risk Diabetic Cardiomyopathy: The ARISE-HF Cardiopulmonary Exercise Testing Subanalysis

Circulation Heart Failure2025-01-303 citations

Echocardiographic phenotypes of diabetic myocardial disorder: evolution over 15 months follow-up in the ARISE-HF trial.

2025-01-133 citations

Relationship between NT-proBNP, echocardiographic abnormalities and functional status in patients with subclinical siabetic cardiomyopathy.

2024-08-023 citations

Racial Differences in Diabetic Cardiomyopathy: The ARISE-HF Trial.

2024-07-015 citations

Randomized Trial of a Selective Aldose Reductase Inhibitor in Patients With Diabetic Cardiomyopathy.

2024-04-0818 citations

Characterizing diabetic cardiomyopathy: baseline results from the ARISE-HF trial

Cardiovascular Diabetology2024-02-0119 citations

450-P: N-Terminal Pro-B Type Natriuretic Peptide Concentrations in Diabetic Cardiomyopathy—Baseline Data from the ARISE-HF Trial

Diabetes2023-06-20

1238-P: The Face of Diabetic Cardiomyopathy—Baseline Characteristics from the ARISE-HF Trial

Diabetes2023-06-20

Rationale and design of the Aldose Reductase Inhibition for Stabilization of Exercise Capacity in Heart Failure Trial (ARISE-HF) in patients with high-risk diabetic cardiomyopathy.

2022-11-1121 citations

1080-P: Addressing the Safety Challenges of Aldose Reductase Inhibition: Development of AT-001 for Diabetic Cardiomyopathy, a Potent and Selective Next Generation Aldose Reductase Inhibitor

Diabetes2020-06-015 citations

462-P: AT-001, a Next Generation Aldose Reductase Inhibitor with Improved Selectivity and Specificity, Protects from Cellular Damage Associated with Hyperglycemia

Diabetes2020-06-013 citations

186-OR: Safety and Tolerability of the Next Generation Aldose Reductase Inhibitor (ARI) AT-001 Supports Initiation of the Pivotal Trial in Diabetic Cardiomyopathy (DbCM)

Diabetes2020-06-01